| Literature DB >> 33173664 |
Maria Lucia Mangialardi1, Ilaria Baldelli2, Marzia Salgarello1, Edoardo Raposio2.
Abstract
INTRODUCTION: Migraine headache (MH) is one of the most common diseases worldwide and pharmaceutical treatment is considered the gold standard. Nevertheless, one-third of patients suffering from migraine headaches are unresponsive to medical management and meet the criteria for "refractory migraines" classification. Surgical treatment of MH might represent a supplementary alternative for this category of patients when pharmaceutical treatment does not allow for satisfactory results. The goal of this article is to provide a comprehensive review of the literature regarding surgical treatment for site I migraine management.Entities:
Year: 2020 PMID: 33173664 PMCID: PMC7647648 DOI: 10.1097/GOX.0000000000003084
Source DB: PubMed Journal: Plast Reconstr Surg Glob Open ISSN: 2169-7574
Six Different Migraine Trigger Sites Corresponding to Branches of the Trigeminal and the Greater Occipital Nerves in 3 Different Craniofacial Regions
| Trigger Site | Trigger Site | Corresponding Nerve |
|---|---|---|
| Site I | Frontal | Supratrochlear and supraorbital nerves |
| Site II | Temporal | Zygomatico-temporal branch of the trigeminal nerve |
| Site III | Septo-nasal | – |
| Site IV | Occipital | Great occipital nerve |
| Site V | Auricolo-temporalis | Auriculo-temporal nerve |
| Site VI | Lesser occipital | Lesser occipital nerve |
Fig. 1.PRISMA guidelines.
Study Characteristics and Data Collection Regarding Surgical Strategies
| Study | Type | Sample (patients) | Surgical Incision | Surgical Strategy |
|---|---|---|---|---|
| Guyuron et al[ | Retrospective analysis | 39 | TP or E or open | Resection of the corrugator and depressor muscles |
| Dirnberger and Becker[ | Prospective | 60 | TP | Resection of the corrugator and depressor muscles, vessels coagulation by bipolar diathermy |
| Bearden and Anderson[ | Prospective | 12 | TP | Resection of the corrugator and depressor muscles, procerus muscle weakening |
| Guyuron et al[ | Double-blind, sham surgery, controlled clinical trial | 29 | TP | Resection of corrugator, depressor and procerus muscle + fat from medial compartment of the upper eyelid to fill any defect left by the excised muscles |
| de Ru et al[ | Prospective | 10 | E | Cleavage of the corrugator muscle |
| Chepla et al[ | Retrospective analysis | 86 | TP or E | Group 1: glabellar myectomy |
| Lee et al[ | Retrospective analysis | 132 | TP or E | Resection of corrugator, depressor, and lateral portion of the procerus + fat from medial compartment of the upper eyelid to fill any defect left by the excised muscles |
| Liu et al[ | Retrospective analysis | 35 | TP or E | – Resection of corrugator, depressor and lateral portion of the procerus + fat from medial compartment of the upper eyelid to fill any defect left by the excised muscles |
| Caruana et al[ | Prospective | 54 | E | Frontal bilateral selective myotomy procedure of procerus, depressor, and corrugator muscles |
| Caruana et al[ | Prospective | 16 | E | Resection of corrugator, depressor, and procerus muscles |
| Polotto et al[ | Retrospective analysis | 43 | E | Selective myotomies of corrugator, depressor, and procerus muscles |
| Raposio and Caruana[ | Prospective | 43 | E | Corrugator, depressor, and procerus muscles section performing one myotomy (full-thickness to reach the subcutaneous tissue) per side parallel and approximately |
| Kurlander et al[ | Retrospective analysis | 34 | TP | Corrugator resection |
| Punjabi et al[ | Cross- sectional study | 185 | TP | Corrugator, depressor, and procerus resection + fat from medial compartment of the upper eyelid to fill any defect left by the excised muscles |
| Gatherwright et al[ | Prospective, | 13 | TP | 4 groups: |
| Filipovic et al[ | Prospective | 22 | E | Complete release of STN and SON by cutting the periosteum at the level of the supraorbital ridge |
| Fallucco et al[ | Cadaveric study | 30 | TP | Transpalpebral bilateral approach |
| Ortiz et al[ | Prospective | 61 | TP | Transpalpebral bilateral approach |
E, endoscopic approach; TP, transpalpebral approach.
Outcomes of Surgical Deactivation of Frontal Trigger Site Migraine
| Study | Sample (patients) | Outcomes Measurements | Follow-up (mo) | Results | Complications |
|---|---|---|---|---|---|
| Guyuron et al[ | 39 | – | 46.5 | 79.5% positive response | –Paresthesia |
| Dirnberger[ | 60 | % reduction of MH days, drugs, side effects, and severity of MH | 6 and 18 | 68.3% positive response | Paraesthesia, disappeared in all patients within 3–9 months. |
| Bearden and Anderson[ | 12 | Onset, frequency, severity, and | 6–19 | 92% →improvement | Any |
| Guyuron et al[ | 29 | –Migraine Disability Assessment | 12 | –Temporary intense | |
| de Ru et al[ | 10 | Pain severity scoring | 3–30 | 90% → lowered pain score | Numbness in 3 patients |
| Chepla et al[ | 86 | MH severity, frequency, and duration | 12 | Not reported | |
| Lee et al[ | 132 | MHI (success defined as | >12 | Not reported | |
| Liu et al[ | 35 | MH frequency, duration | 12–126 | 77% → positive response | Not reported |
| Caruana et al[ | 54 | 36-item short questionnaire | 24 | Not reported | |
| Caruana et al[ | 16 | Headache questionnaire | – | 81.5% → positive response | Not reported |
| Polotto et al[ | 43 | Headache questionnaire | 24 | 93.3% → positive response to the surgery: | Not reported |
| Raposio and Caruana[ | 43 | Headache questionnaire | 6 and 24 | Not reported | |
| Kurlander et al[ | 34 | Frontal-specific MHI | 12 | 88% → positive response | Numbness →32.1% |
| Punjabi et al[ | 185 | Migraine headache questionnaire | 13 | 17.8% of the cohort reported new postoperative migraines | Not reported |
| Gatherwright et al[ | 13 | Migraine headache severity | 21.6 (7.6–34.1) | MHI: from 52.6 (3.8–85) to 4.7(0–21.3), | Not reported |
| Filipovic et al[ | 22 | Daily headache diary | 12–107 (mean: 29.5) | VAS headache intensity from 8.10 to 1.3 at 3 months after surgery and to 1.09 at 12 months after surgery | –Transient paresthesia → 2 patients (3 months duration) |
| Fallucco et al[ | 30 | – | – | –Supraorbital foramen → 26.6% of cases | – |
| Ortiz et al[ | 61 | – | – | –Supraorbital foramen → 41% of cases | – |
BTA, botulinum toxin type A; MFD, migraine-free days; MSQEM, Migraine-Specific Quality of Life.